Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans
- PMID: 3335637
- PMCID: PMC442496
- DOI: 10.1172/JCI113298
Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans
Abstract
We examined plasma levels of the sympathetic neurotransmitter norepinephrine (NE) and its deaminated metabolite dihydroxyphenylglycol (DHPG) during supine rest in healthy human subjects and in sympathectomized patients, during physiological (tilt) or pharmacological (yohimbine, clonidine) manipulations known to affect sympathetically mediated NE release, during blockade of neuronal uptake of NE (uptake-1) using desipramine, and during intravenous infusion of NE. Healthy subjects had a mean arteriovenous increment in plasma DHPG in the arm (10%, P less than 0.05), whereas sympathectomized patients had a mean arteriovenous decrement in DHPG in the affected limb (mean decrease 21%, P less than 0.05 compared with healthy subjects). Tilt and yohimbine, which stimulate, and clonidine, which inhibits, release of endogenous NE, produced highly correlated changes in plasma NE and DHPG (r = 0.94). Pretreatment with desipramine abolished DHPG responses to yohimbine while enhancing NE responses. To attain a given increase in plasma DHPG, about a tenfold larger increment in arterial NE was required during NE infusion than during release of endogenous NE. When plasma NE was markedly suppressed after administration of clonidine, plasma DHPG decreased to a plateau level of 700-800 pg/ml. The results indicate that (i) plasma DHPG in humans is derived mainly from sympathetic nerves; (ii) increments in plasma DHPG during stimulation of NE release result from uptake of NE into sympathetic nerve endings and subsequent intraneuronal conversion to DHPG; (iii) plasma DHPG under basal conditions probably is determined mainly by net leakage of NE into the axonal cytoplasm from storage vesicles; and (iv) increments in NE concentrations at neuronal uptake sites can be estimated by simultaneous measurements of DHPG and NE during NE infusion and NE release. Measurement of NE and DHPG provides unique clinical information about sympathetic function.
Similar articles
-
Dihydroxyphenylglycol and intraneuronal metabolism of endogenous and exogenous norepinephrine in the rat vas deferens.J Pharmacol Exp Ther. 1987 May;241(2):547-53. J Pharmacol Exp Ther. 1987. PMID: 3572811
-
Plasma dihydroxyphenylglycol (DHPG) in the in vivo assessment of human neuronal norepinephrine metabolism.Life Sci. 1985 Sep 16;37(11):1033-8. doi: 10.1016/0024-3205(85)90593-4. Life Sci. 1985. PMID: 4033349
-
Dialysate dihydroxyphenylglycol as a window for in situ axoplasmic norepinephrine disposition.Neurochem Int. 2001 Mar;38(3):287-92. doi: 10.1016/s0197-0186(00)00079-6. Neurochem Int. 2001. PMID: 11099788
-
Circulating dihydroxyphenylglycol and norepinephrine concentrations during sympathetic nervous system activation in patients with pheochromocytoma.J Clin Endocrinol Metab. 1994 Dec;79(6):1609-14. doi: 10.1210/jcem.79.6.7989464. J Clin Endocrinol Metab. 1994. PMID: 7989464
-
Implications of plasma levels of catechols in the evaluation of sympathoadrenomedullary function.Am J Hypertens. 1989 Mar;2(3 Pt 2):133S-139S. doi: 10.1093/ajh/2.3.133s. Am J Hypertens. 1989. PMID: 2493793 Review.
Cited by
-
Tilt-evoked, breathing-driven blood pressure oscillations: Independence from baroreflex-sympathoneural function.Clin Auton Res. 2024 Feb;34(1):125-135. doi: 10.1007/s10286-024-01022-7. Epub 2024 Mar 6. Clin Auton Res. 2024. PMID: 38446362 Free PMC article.
-
Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.Hypertension. 2012 Mar;59(3):650-6. doi: 10.1161/HYPERTENSIONAHA.111.184812. Epub 2012 Feb 6. Hypertension. 2012. PMID: 22311903 Free PMC article. Clinical Trial.
-
Roles of catechol neurochemistry in autonomic function testing.Clin Auton Res. 2018 Jun;28(3):273-288. doi: 10.1007/s10286-018-0528-9. Epub 2018 Apr 28. Clin Auton Res. 2018. PMID: 29705971 Free PMC article. Review.
-
Clinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension.Hypertension. 2025 Mar;82(3):489-497. doi: 10.1161/HYPERTENSIONAHA.124.24050. Epub 2024 Dec 27. Hypertension. 2025. PMID: 39727053 Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension.Clin Auton Res. 2021 Jun;31(3):395-403. doi: 10.1007/s10286-021-00800-x. Epub 2021 Mar 29. Clin Auton Res. 2021. PMID: 33782836 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical